By Chad Terhune
(Reuters) - Medication costs for COVID-19 patients hospitalized in the United States have dropped sharply since May, reflecting advances in treatment, shorter stays and use of cheaper generic drugs.
But costs may rise again as hospitals start to pay for Gilead Sciences Inc's remdesivir.
Research by the health data firm IllumiCare and exclusively shared with Reuters found that hospitals spent $1,090 per COVID-19 patient on medication in July. That was down...